Nurix, Inc. has entered into a strategic collaboration with Celgene Corp. for the discovery, development and commercialization of novel small molecule therapeutics in oncology, inflammation and immunology, including immuno-oncology. The companies will work to advance new therapies that function through the ubiquitin proteasome system (UPS) to modulate protein homeostasis, a fundamental cellular process controlling protein levels. Mutations in UPS genes are common drivers of many human cancers.  ...